EWTX Edgewise Therapeutics, Inc. Loading...

Loading chart...
Top Calls

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
13:12
Nov 05
seedy19tron
EWTX dosing advantage, cleared M&A path
Calls a dosing-driven bull case for EWTX, arguing its 50/100/150 escalation avoids echo workflow, giving it an advantage over CYTK and BMY, with M&A expected to resolve before Phase 3 starts.
EWTX Edgewise Therapeutics, Inc. Long — —
16:24
Oct 20
seedy19tron
EWTX Sevasemten Ph3 catalyst
Holds EWTX and elaborates that Sevasemten Ph3 is due any day; a hit could bring ~$1B over two years (~25% of market cap), with FDA alignment seen as clearing a path for a buyer to run Ph3.
EWTX Edgewise Therapeutics, Inc. Long Position: Holding —
00:09
Oct 20
seedy19tron
Owns too little $EWTX
Says they do not own enough $EWTX, indicating a current long position they view as undersized, without detailing a thesis or target.
EWTX Edgewise Therapeutics, Inc. Long 2ND Position: Holding —
Log in to see ideas

About EWTX Investor Commentary

Across the available history and selected sources, Buzzberg tracks EWTX (Edgewise Therapeutics, Inc.) across 2 sources: 12 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 32% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 37 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish, 3 other directions. Latest voices: seedy19tron.